Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CRB-701
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Corbus Pharmaceuticals
Deal Size : $692.5 million
Deal Type : Licensing Agreement
Details : The agreement covers exclusive commercialization rights to CRB-701, a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4, in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, an...
Product Name : CRB-701
Product Type : Antibody-drug Conjugate
Upfront Cash : $7.5 million
February 13, 2023
Lead Product(s) : CRB-701
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Corbus Pharmaceuticals
Deal Size : $692.5 million
Deal Type : Licensing Agreement
Reset All
